A new article published in Pharmacological Research discussed that biotechnological products are an invaluable resource in the treatment of patients with inflammatory rheumatic diseases (IRD) who are non-responsive or intolerant to conventional therapies. However, they render increased direct costs and represent a significant economic burden to healthcare systems. The authors reported that since biosimilars are identical and more affordable versions of previously licensed biotechnological, they could contribute to healthcare system sustainability and reduce inequities in treatment access.
The landmark approval of CT-P13 as the first infliximab biosimilar paved the way for new infliximab but also etanercept, adalimumab and rituximab biosimilars. In Europe, North America and some Asian countries, development is strictly regulated and only those presenting a totality-of-evidence dossier…
